References
- Marketsandmarkets.com. Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) and by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) – Trends and Global Forecast to 2020. 2015.
- Martinez-Ramirez D, Hu W, Bona AR, et al. Update on deep brain stimulation in Parkinson’s disease. Transl Neurodegener. [Internet]. 2015;4:1–8. Available from: http://dx.doi.org/10.1186/s40035-015-0034-0.
- Benazzouz A, Piallat B, Pollak P, et al. Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci Lett. 1995;189:77–80. [Internet]. [cited 2017 Oct 31]. Available from: https://www.sciencedirect.com/science/article/pii/0304394095114556.
- Benazzouz A, Gao DM, Ni ZG, et al. Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience. 2000;99:289–295. [Internet]. Available from: http://www.sciencedirect.com/science/article/pii/S0306452200001998.
- Lee KH, Chang S-Y, Roberts DW, et al. Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus. J Neurosurg. 2004;101:511–517.
- Tawfik VL, Chang S-Y, Hitti FL, et al. Deep brain stimulation results in local glutamate and adenosine release: investigation into the role of astrocytes. Neurosurgery. 2010;67:367–375.
- Vedam-Mai V, van Battum EY, Kamphuis W, et al. Deep brain stimulation and the role of astrocytes. Mol Psychiatry. 2012;17:124–131. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21625231.
- Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896–908.
- Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65:586–595.
- Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301:63–73.
- Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581–591.
- Hagell P, Nilsson MH. The 39-item Parkinson's Disease Questionnaire (PDQ-39): is it a unidimensional construct? Ther Adv Neurol Disord. 2009;2:205–214.
- Bhidayasiri R, Martinez-Martin P. Chapter six - clinical assessments in Parkinson’s disease: scales and monitoring. In: Bhatia KP, Chaudhuri KR, Stamelou MBT-IR of N, editors. Parkinsons Disease. [Internet]. Academic Press; 2017. p. 129–182. Available from: http://www.sciencedirect.com/science/article/pii/S0074774217300016.
- Lyons KE, Pahwa R. Deep brain stimulation and essential tremor. J Clin Neurophysiol. 2004;21:2–5. [Internet]. Available from: https://journals.lww.com/clinicalneurophys/Fulltext/2004/01000/Deep_Brain_Stimulation_and_Essential_Tremor.2.aspx.
- Putzke JD, Wharen RE, Obwegeser AA, et al. Thalamic deep brain stimulation for essential tremor: recommendations for long-term outcome analysis. Can J Neurol Sci Le J Can des Sci Neurol. [Internet]. 2004;31:333–342. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=15376477&retmode=ref&cmd=prlinks%5Cnpapers2://publication/uuid/46CB0CEE-570C-4EB2-9410-1F994267838F.
- Bryant JA, De Salles A, Cabatan C, et al. The impact of thalamic stimulation on activities of daily living for essential tremor. Surg Neurol. 2003;59:479–479.
- Koller WC, Lyons KE, Wilkinson SB, et al. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. Mov Disord. 2001;16:464–468. [Internet]. Available from: http://dx.doi.org/10.1002/mds.1089.
- Pahwa R, Lyons KE, Wilkinson SB, et al. Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. Mov Disord. 2001;16:140–143.
- Lee JYK, Kondziolka D. Thalamic deep brain stimulation for management of essential tremor. J Neurosurg. 2005;103:400–403. [Internet]. Available from: http://thejns.org/doi/10.3171/jns.2005.103.3.0400.
- Cooperrider J, Furmaga H, Plow E, et al. Chronic deep cerebellar stimulation promotes long-term potentiation, microstructural plasticity, and reorganization of perilesional cortical representation in a rodent model. J Neurosci 2014;34:9040–9050. [Internet]. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.0953-14.2014.
- Machado AG, Cooperrider J, Furmaga HT, et al. Chronic 30-Hz deep cerebellar stimulation coupled with training enhances post-ischemia motor recovery and peri-infarct synaptophysin expression in rodents. Neurosurgery 2013;73:344–353. [Internet]. Available from: http://dx.doi.org/10.1227/01.neu.0000430766.80102.ac.
- Câmara R, Griessenauer CJ. Anatomy of the vagus nerve. In: Nerves Nerve Inj. [Internet]. Elsevier; 2015. p. 385–397. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780124103900000287.
- Ben-Menachem E. Vagus nerve stimulation, side effects, and long-term safety. J Clin Neurophysiol. 2001;18:415–418.
- Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51:48–55.
- The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology. 1995;45:224–230.
- Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav 2011;20:57–63.
- Bodin E, Le Moing A-G, Bourel-Ponchel E, et al. Vagus nerve stimulation in the treatment of drug-resistant epilepsy in 29 children. Eur J Paediatr Neurol. 2016;20:346–351. [Internet]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1090379816000313.
- Ogbonnaya S, Kaliaperumal C. Vagal nerve stimulator: evolving trends. J Nat Sci Biol Med. 2013;4:8. [Internet]. Available from: http://www.jnsbm.org/text.asp?2013/4/1/8/107254.
- Krahl SE, Clark KB, Smith DC, et al. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia. 1998;39:709–714.
- Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand. 2011;124:5–15.
- Henry TR, Bakay RA, Votaw JR, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia. 1998;39:983–990.
- Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53:115–118.
- Manta S, Dong J, Debonnel G, et al. Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J Psychiatry Neurosci. 2009;34:272–280.
- Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther. 2006;318:890–898. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16690723.
- Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280–287. [Internet]. Available from: http://dx.doi.org/10.1016/S0006-3223(01)01343-9.
- Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66:1097–1104.
- Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatr. 2017;174:640–648. [Internet]. Available from: https://doi.org/10.1176/appi.ajp.2017.16010034.
- Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. J Exp Med. 2012;209:1057–1068.
- Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. Annu Rev Immunol. 2012;30:313–335. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22224768.
- Tracey KJ. The inflammatory reflex. Nature. 2002;420:853–859. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12490958.
- Koopman FA, Schuurman PR, Vervoordeldonk MJ, et al. Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis? Best Pract Res Clin Rheumatol. 2014;28:625–635. [Internet]. Available from: http://dx.doi.org/10.1016/j.berh.2014.10.015.
- Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA. 2016;113:8284–8289. [Internet]. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1605635113.
- PRESS RELEASE: SetPoint Medical Presents Positive Results In Ongoing Crohn’s Disease Study [Internet]. 2017. Available from: https://setpointmedical.com/setpoint-medical-presents-positive-results-in-ongoing-crohns-disease-study/.
- Yuan H, Silberstein SD. Vagus nerve stimulation and headache. Headache. 2017;57:29–33.
- ElectroCore. GammaCore: instructions for use for GammaCore. 2016.
- PRESS RELEASE: electroCore Announces Results from gammaCore (non-invasive vagus nerve stimulator) Study in Migraine at the 18th Congress of the International Headache Society [Internet]. 2017. Available from: http://www.electrocore.com/electrocore-announces-results-from-gammacore-non-invasive-vagus-nerve-stimulator-study-in-migraine-at-the-18th-congress-of-the-international-headache-society.
- Berthoud H-R. The vagus nerve, food intake and obesity. Regul Pept. 2008;149:15–25. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597723/.
- de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J Physiol (Lond). 2016;594:5791–5815.
- Burneo JG, Faught E, Knowlton R, et al. Weight loss associated with vagus nerve stimulation. Neurology. 2002;59:463–464.
- Pardo JV, Sheikh SA, Kuskowski MA, et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. Int J Obes. 2007;31:1756–1759. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365729/.
- Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA. 2014;312:915–922.
- Meyers EE, Kronemberger A, Lira V, et al. Contrasting effects of afferent and efferent vagal nerve stimulation on insulin secretion and blood glucose regulation. Physiol Rep. 2016;4:e12718. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759047/.
- Holst JJ, Gronholt R, Schaffalitzky de Muckadell OB, et al. Nervous control of pancreatic endocrine secretion in pigs. I. Insulin and glucagon responses to electrical stimulation of the vagus nerves. Acta Physiol Scand. 1981;111:1–7.
- Khodaparast N, Hays SA, Sloan AM, et al. Vagus nerve stimulation during rehabilitative training improves forelimb strength following ischemic stroke. Neurobiol Dis. 2013;60:80–88.
- Hays SA, Khodaparast N, Hulsey DR, et al. Vagus nerve stimulation during rehabilitative training improves functional recovery after intracerebral hemorrhage. Stroke. 2014;45:3097–3100. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25147331.
- Hays SA, Rennaker RL, Kilgard MP. Targeting plasticity with vagus nerve stimulation to treat neurological disease. Prog Brain Res. 2013;207:275–299.
- Capone F, Miccinilli S, Pellegrino G, et al. Transcutaneous vagus nerve stimulation combined with robotic rehabilitation improves upper limb function after stroke. Neural Plast.[Internet]. 2017;2017:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29375915.
- Sullivan KJ, Tilson JK, Cen SY, et al. Fugl-meyer assessment of sensorimotor function after stroke: Standardized training procedure for clinical practice and clinical trials. Stroke. 2011;42:427–432.
- Jankowska EA, Ponikowski P, Piepoli MF, et al. Autonomic imbalance and immune activation in chronic heart failure – Pathophysiological links. Cardiovasc Res. 2006;70:434–445. [Internet]. Available from: http://dx.doi.org/10.1016/j.cardiores.2006.01.013.
- Champion HC, Skaf MW, Hare JM. Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev. 2003;8:35–46.
- Aukrust P, Gullestad L, Ueland T, et al. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37:74–85.
- Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004;109:120–124.
- Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008;10:884–891.
- Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015;36:425–433.
- De Ferrari GM, Crijns H, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32:847–855.
- Premchand RK, Sharma K, Mittal S, et al. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail. 2014;20:808–816.
- Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016;68:149–158.
- PRESS RELEASE: Endonovo reports pre-clinical data demonstrating ImmunotronicsTM reduced infarct size and inhibited fibrosis following myocardial infarction. 2018.
- Kumar K, Wilson JR, Taylor RS, et al. Complications of spinal cord stimulation, suggestions to improve outcome, and financial impact. J Neurosurg Spine .[Internet]. 2006;5:191–203. Available from: https://doi.org/10.3171/spi.2006.5.3.191.
- Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;150:971–979. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5320816.
- Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain. 2007;132:179–188.
- North RB, Kidd DH, Farrokhi F, et al. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56:98–106.
- Castillo-Guzmán S, Nava-Obregón TA, Palacios-Ríos D, et al. Complex regional pain syndrome (CRPS), a review. Med Univ 2015;17:114–121. [Internet]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1665579615000320.
- Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 2000;343:618–624. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10965008.
- Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain. Arthritis Care Res. 2011;63:S240–S252. [Internet]. Available from: http://doi.wiley.com/10.1002/acr.20543.
- Kemler MA, de Vet HCW, Barendse GAM, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome type I: five-year final follow-up of patients in a randomized controlled trial. JNS. 2008;108:292–298. [Internet]. Available from: http://thejns.org/doi/10.3171/JNS/2008/108/2/0292.
- Kemler MA, De Vet HCW, Barendse GAM, et al. The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years’ follow-up of the randomized controlled trial. Ann Neurol. 2004;55:13–18. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14705107.
- Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Reports Urol. 2016;Volume 8:193–199.
- Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.
- Kohli N, Patterson D. InterStim therapy: a contemporary approach to overactive bladder. Rev Obstet Gynecol. 2009;2:18–27.
- Latini JM, Alipour M, Kreder K. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology. 2006;67:550–554.
- van Kerrebroeck PV, van Voskuilen AC, Heesakkers J, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029–2034.